Anika Therapeutics (ANIK) Gains from Investment Securities (2020 - 2021)

Anika Therapeutics' (ANIK) quarterly Gains from Investment Securities came in at $825000.0 in Q4 2021, up 106.6% year-on-year from $399322.4 in Q4 2020, and up 123.91% on a QoQ basis from -$3.4 million in Q3 2021.

Anika Therapeutics (ANIK) Gains from Investment Securities (2020 - 2021) Analysis & Trends

Anika Therapeutics (ANIK) has 2 years of Gains from Investment Securities data on file, last reported at $825000.0 in Q4 2021.

  • On a quarterly basis, Gains from Investment Securities rose 106.6% year-over-year to $825000.0 in Q4 2021; TTM through Sep 2022 was $825000.0, a 102.4% increase from a year earlier, with the FY2021 full-year figure at -$21.1 million, up 26.41% from the prior year.
  • Gains from Investment Securities for Q4 2021 stood at $825000.0, up from -$3.4 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for ANIK reached as high as $4.2 million in Q2 2020 and fell as low as -$24.5 million in Q1 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 89.28 Bn 87.42 Bn -
2 Teva Pharmaceutical Industries 35.97 Bn 32.23 Bn 1.97 Bn
3 Zoetis 32.42 Bn 30.48 Bn 1.62 Bn
4 Takeda Pharmaceutical 27.48 Bn 23.42 Bn 4.39 Bn
5 United Therapeutics 22.89 Bn 20.73 Bn 648.10 Mn
6 RedHill Biopharma 22.11 Bn 22.11 Bn -
7 Viatris 20.44 Bn 18.64 Bn 1.16 Bn
8 Neurocrine Biosciences 17.76 Bn 16.44 Bn 800.70 Mn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn
10 Anika Therapeutics 203.64 Mn 136.85 Mn 19.00 Mn

Historic Data

Download Data
DateValue
Dec 31, 2021 825,000.00
Dec 31, 2021 825,000.00
Sep 30, 2021 -3.45 Mn
Sep 30, 2021 -3.45 Mn
Jun 30, 2021 -13.65 Mn
Jun 30, 2021 -13.65 Mn
Mar 31, 2021 -4.82 Mn
Mar 31, 2021 -4.82 Mn
Dec 31, 2020 -12.50 Mn
Dec 31, 2020 -12.50 Mn
Sep 30, 2020 4.15 Mn
Sep 30, 2020 4.15 Mn
Jun 30, 2020 4.20 Mn
Jun 30, 2020 4.20 Mn
Mar 31, 2020 -24.52 Mn
Mar 31, 2020 -24.52 Mn